Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel cancer immunotherapy products based on the chimeric antigen receptor engineered T (CAR T) cell technology. The company's CAR T product candidates include MB-101, a IL13Ra2 CAR T cell program which is in Phase I clinical study for glioblastoma; and MB-102, a CD123 CAR T cell program to treat acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm; and MB-106, a CD20 CAR T cell program that is in Phase I clinical study for the treatment of B cell non-Hodgkin lymphoma. It also develops MB-104, a CS1 CAR T, which is in Preclinical study for multiple myeloma and light chain amyloidosisy; MB-103, a human epidermal growth factor receptor 2 CAR T that is in Preclinical study to treat glioblastoma multiforme and metastatic breast cancer to brain; and MB-105, a prostate stem-cell antigen CAR T for prostate and pancreatic cancers. The company has a partnership agreement with the City of Hope National Medical Center and Fred Hutchinson Cancer Research Center to develop proprietary CAR T therapies across various cancers. It also holds a license agreement with Harvard University; and a research collaboration agreement with Beth Israel Deaconess Medical Center for the development of CRISPR/Cas9-enhanced CAR T therapies for the treatment of cancer. The company was incorporated in 2015 and is based in New York, New York. Mustang Bio, Inc. is a subsidiary of Fortress Biotech, Inc.